After Crashing 27% in the Past Month, Is Viking Therapeutics Stock a Bargain Buy Right Now?

There's a growing number of companies entering the weight loss space, focusing on GLP-1 drugs which can be game changers for their businesses. And one of them is Viking Therapeutics (NASDAQ: VKTX), which has a promising GLP-1 treatment in development that investors are hopeful will generate billions in revenue for the modestly sized healthcare company. It may even lead to an acquisition.In the past month, however, excitement around Viking has cooled, considerably. During November, the stock fell by 27%, hitting lows it hasn't been at in months. At a cheaper valuation, has Viking Therapeutics become too good of a buy to pass up right now?Although it looks like there may be some mounting pessimism surrounding Viking Therapeutics stock recently, its shares are still up more than 180% this year, as of the end of last week. Investors may simply be cashing out some profits heading into the close of 2024.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool